PA-PMI
22.8.2022 14:02:14 CEST | Business Wire | Press release
Project Management Institute (PMI) today announced that its Board of Directors has named Pierre Le Manh as President and Chief Executive Officer (CEO).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005706/en/
Starting September 1, Pierre Le Manh, a veteran CEO of professional services and knowledge industries, will lead PMI’s fast-growing global organization and oversee the continued execution of PMI’s Impact Strategy. In his role, Pierre will also serve as the lead advocate for PMI’s global organization and close to a hundred million project professionals worldwide.
“We are very excited to bring Pierre Le Manh on board after a thorough selection process,” said Jennifer Tharp, PMP, Chair of PMI’s Board of Directors. “We have big ambitions for the future of our profession and the Project Management Institute as a leading global organization. Pierre brings the global experience and credentials to accelerate PMI’s current business and further our innovation and transformation journey. As Michael DePrisco will resume his responsibilities as PMI’s chief operating officer, the Board and myself want to express our gratitude to Michael for serving as interim CEO during the selection process.”
Pierre Le Manh has served in CEO roles for over 20 years at knowledge, research, and technology-based companies worldwide. He has lived and worked in Paris, Montreal, London, Rome, and New York City. He brings a proven track record of growth, transformation, and globalization and a passion for team building and nurturing culture.
“Think about what project professionals have achieved across all sectors of the economy and society: from construction to technology, from healthcare to government, from consumer goods to infrastructure, from arts to sciences,” said Le Manh. “Maybe even more importantly, think of the daunting tasks ahead of them when humanity has no other choice than to pursue more sustainable development in the future. Without competent professionals to lead and run projects, ideas cannot be made a reality. Project professionals are the doers and builders of transformation.”
“I am eager to work with PMI’s Board, Michael DePrisco and the leadership team, and our growing global team of more than 700 permanent employees to take on the challenges of a new era, innovate and build upon PMI’s status as a fast-growing global leader in professional development, education, and upskilling,” continued Le Manh. “I enthusiastically look forward to meeting and working with the greater global mission-driven community of changemakers of more than 300 chapters, 10,000 volunteers, and close to 700,000 active PMI members to create better outcomes for individuals, businesses, and society worldwide.”
Before joining PMI, Pierre Le Manh recently led a project for the North American expansion of Galileo Global Education, a European leader in post-secondary higher education and education technology. Until 2021, he served as the Chief Executive Officer of North America and Global Deputy CEO of Ipsos, the global leader in market research and data analytics, where he played a key leadership role in the company’s global expansion for over 15 years, first as CEO for EMEA and then as global head of several professional practices before heading the North American business. Before Ipsos, he held several other CEO positions in technology-based services and publishing.
“I am very excited to leverage the broad and deep experience I have gained over my career to lead the PMI organization and, in particular, to create a stronger membership experience for project professionals seeking lifelong learning and development opportunities and for corporate partners investing in reskilling and upskilling their workforce,” Le Manh said.
About Project Management Institute (PMI)
Project Management Institute (PMI) is the leading professional development organization for project management and the authority for a growing global community of millions of professionals of the project economy who use project, program, and portfolio management skills and competencies.
Building on a proud legacy dating to 1969, PMI is a not-for-profit for-purpose organization working in nearly every country to advance careers, strengthen organizational success, and enable project professionals and changemakers with new skills and ways of working to maximize their impact. PMI offerings include globally recognized standards, certifications, online courses, thought leadership, tools, digital publications, and communities.
PMI empowers people to make ideas a reality and helps professionals and changemakers create better outcomes for businesses, communities, and society worldwide. Through global advocacy, networking, collaboration, research, and education, PMI prepares organizations and individuals at every stage of their career journey to work smarter to drive success in a world of change.
Visit us at www.PMI.org , LinkedIn , https://www.facebook.com/PMInstitute , and on Twitter @PMInstitute .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220817005706/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
